LTS Executive and Leadership Team

Yuval Saranga, the Chief Financial Officer at LTS, directs all financial operations and strategic fiscal planning. Overseeing budgeting, forecasting, and financial reporting, Saranga ensures robust financial health and supports the company's global expansion initiatives. This leadership role involves managing capital allocation, optimizing investment strategies, and maintaining strong relationships with financial institutions. By driving financial efficiency, Yuval Saranga directly impacts the company's ability to fund research and development for advanced drug delivery systems. Ultimately, Saranga secures long-term financial stability and growth for LTS's pharmaceutical technology operations.

Andrei Yosef, the LTS Device Technologies President & General Manager at LTS, directs the strategic growth and operational execution of the company's device technology portfolio. Yosef oversees the entire lifecycle of drug delivery devices, from initial concept and design through to large-scale manufacturing and global commercialization. This leadership position involves ensuring seamless integration between research, development, and production, while maintaining the highest standards of quality and regulatory compliance across all operations. By driving the device technology division, Andrei Yosef ensures LTS partners receive comprehensive support in bringing advanced, patient-centric therapies to market. Ultimately, Yosef's management strengthens LTS's position as a leading contract development and manufacturing partner in the global healthcare industry.

Ori Ben-Tur, the Chief Technology Officer & Vice President, Research & Development at LTS, architects the company's technological vision and drives innovation in drug delivery systems. Ben-Tur oversees all research and development activities, focusing on pioneering transdermal patches, oral thin films, and microneedle patch systems. This critical role involves guiding scientific exploration, fostering cross-functional collaboration between research and manufacturing, and ensuring the development of cutting-edge, patient-friendly therapies. By leading the R&D pipeline, Ori Ben-Tur ensures LTS remains at the forefront of pharmaceutical technology, translating complex scientific concepts into viable commercial solutions. Ultimately, Ben-Tur's leadership advances the company's mission to improve patient adherence and treatment outcomes through advanced drug administration.

Shay Sharvit, the Senior Reserach Engineer - Chief Technology Officer Office at LTS, contributes critical engineering expertise to the advancement of drug delivery technologies. Sharvit focuses on the practical application of research findings, supporting the development and refinement of systems like wearable injection devices and topical patch solutions. This role involves detailed technical analysis, problem-solving in product development, and ensuring the manufacturability of innovative delivery platforms. By collaborating closely with the Chief Technology Officer, Shay Sharvit helps translate complex scientific designs into functional, scalable pharmaceutical technologies. Ultimately, Sharvit's engineering contributions are vital to enhancing patient convenience and improving the efficacy of chronic condition management through LTS's specialized systems.